Stereotactic Radiosurgery Combination With Anlotinib for Limited Brain Metastases in NSCLC (AnloSBRT)
Stereotactic Radiosurgery Combination With Anlotinib for Limited Brain Metastases in Non-small Cell Lung Cancer
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100191
- Department of Radiation Oncology Cancer Center, Peking University Third Hospital 49# North Garden Rd.,Haidian Dist.
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients pathologically diagnosed as non-small cell lung cancer, with brain metastases and measurable lesions;
- Patients aged between 18 -80 years; with expected survival time>3 months.
- Patients with no more than 5 brain metastases
Patients with normal organ function within 7 days prior to treatment, the following criteria are met:
- blood routine examination criteria : i) hemoglobin (HB) ≥90g/L; ii) absolute neutrophil count (ANC) ≥1.5×10e9/L; iii) platelet (PLT) ≥80×10e9/L; b) biochemical tests meet the following criteria: i) total bilirubin (TBIL) ≤1.5 times of upper limit of normal (ULN); ii) alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 ULN, if liver metastasis occurred, ALT and AST ≤5 ULN; iii) serum creatinine (Cr) ≤1.5 ULN or creatinine clearance (CCr) ≥60mL/min;
Exclusion Criteria:
- Patients who had previously used antiangiogenic agents within 1 month;
- Patients with small cell lung cancer (including small cell carcinoma and non-small cell carcinoma mixed lung cancer);
- Patient with lung squamous cell carcinoma that involved pulmonary hilar, or non-small cell lung cancer with hemoptysis;
- Patients with cerebral infarction and cerebral hemorrhage;
- Patients without perilesional edema;
- Patients with more than grade 2 (NCI-CTCAE v4.0) acute toxicity reaction due to any previous treatment.
- Patients with factors that affect oral medication (such as cannot swallow, chronic diarrhea and intestinal obstruction, etc.);
- Patients with visceral dissemination or severe symptoms, which could cause death in short term;
- Patients with any other severe and/or uncontrolled disease;
- Patients who received a surgery, a biopsy or a significant traumatic injury within 1 month;
- Patients with any signs or medical history of bleeding, unhealed wounds, ulcers or fractures, regardless of the severity;
- Patients underwent artery or venous thrombotic events within 2 months, such as deep vein thrombosis and pulmonary embolism;
- Patients with a history of psychotropic medicine abuse and cannot quit or have mental disorders;
- Patients with disease which will severely endanger their security and could not complete this study, according to the judgement of researchers;
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Anlotinib group
Patients in Anlotinib group took Anlotinib 1 week before the MRI-based simulation,12mg/d QD,day1~14, 21d/cycle.
All patients received SBRT for brain metastases.
|
Anlotinib is a novel multi-target tyrosine Kinase inhibitor that inhibits VEGFR2/3, FGFR1-4, PDGFD α/β, c-Kit and Ret. Stereotactic Radiosurgery Stereotactic Radiosurgery as the initial treatment of non small cell lung cancer patients with limited brain metastases
Other Names:
|
|
SBRT group
Patients in SBRT group took no anti-angiogenic drugs.
All patients received SBRT for brain metastases.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
PFS
Time Frame: 1 years
|
progression-free survival
|
1 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
iORR
Time Frame: 3 months
|
intracranial objective response rate
|
3 months
|
|
iPFS
Time Frame: 3 months
|
intracranial progression-free survival
|
3 months
|
|
ORR
Time Frame: 3 months
|
objective response rate
|
3 months
|
|
DCR
Time Frame: 3 months
|
disease control rate
|
3 months
|
|
OS
Time Frame: 1 years
|
overall survival
|
1 years
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neoplasms
- Neoplasms by Site
- Central Nervous System Neoplasms
- Nervous System Neoplasms
- Brain Neoplasms
- Physiological Effects of Drugs
- Antineoplastic Agents
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Angiogenesis Inhibitors
Other Study ID Numbers
Other Study ID Numbers
- AnloSBRT
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.